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PREVENTION OF THROMBOEMBOLIC 
COMPLICATIONS IN PATIENTS WITH ATRIAL 
FIBRILLATION AFTER CORONARY ARTERY STENTING
E.P. Panchenko, MD, Prof.
Myasnikov Research Institute of Clinical Cardiology,
Russian Cardiology Research and Production Complex,
Russia’s Ministry of Health, Moscow
A trial fibrillation is one of the most common cardio-vascular diseases. In atrial fibrillation the incidenceof systemic thromboembolism and stroke increases
fivefold. Coronary artery stenting in coronary artery disease
is another risk factor for thrombotic events. The article dis-
cusses the problem of anticoagulation therapy in patients
with atrial fibrillation after coronary artery stenting.
THE APPROPRIATENESS OF ANTITHROMBOTIC 
THERAPY IN NON-VALVULAR ATRIAL FIBRILLATION 
IN CLINICAL PRACTICE
Baranova1,2 E.I., Soboleva1,2 A.V, Aznauryan1 R.S., 
Ionin1 V.A., Chubenko1,2 E.A., Katsap1 A.A., Yatsuk1,2 D.I.
1 St. Petersburg State Medical University named after aca-
demician I.P. Pavlov, the Ministry of Health of the RF;
2 Federal North-West Medical Research Centre, the Ministry
of Health of the RF.
A im. To assess the risk of stroke and type ofantithrombotic therapy at the outpatient and inpa-tient treatment stages in patients with non-valvular
atrial fibrillation. Material and methods. 576 medical records
of patients admitted to cardiology unit in 2013 were stud-
ied. Risk factors for stroke and systemic embolism were
evaluated using the CHA2DS2-VASc score and antithrom-
botic therapy was considered. Results. Atrial fibrillation was
diagnosed in 26.3% of patients. Non-valvular atrial fibrilla-
tion was diagnosed in 82.2% of those. 111 (88.8%) patients
had a score of 2 or more on the CHA2DS2-VASc, 13 (10.4%)
patients had a score of 1 and only 1 patient had a score of 0
points. The average CHA2DS2-VASc score in patients with
atrial fibrillation was 3,9 ± 1,0. Only 40% of patients with
non-valvular atrial fibrillation received anticoagulants at
prehospital stage. 38.4% of patients received antiplatelet
agents and 21.6% of patients did not receive antithrombotic
therapy. Only 26.8% of patients taking warfarin had target
INR at admission. Anticoagulant therapy was prescribed to
93 outpatients (74.4%). Conclusions. A majority of patients
with non-valvular atrial fibrillation who were hospitalized in
the cardiology clinic had a high risk of stroke and systemic
embolism, though they did not receive appropriate
antithrombotic therapy. In patients with non-valvular atrial
fibrillation, the risk of stroke should be assessed using the
CHA2DS2-VASc score, and those at high risk should receive
anticoagulant therapy.
KEYWORDS: atrial fibrillation, new direct oral anticoagu-
lants, anticoagulant therapy.
CARDIOVERSION USING RIVAROXABAN 
IN PATIENTS WITH NON-VALVULAR ATRIAL 
FIBRILLATION: RESULTS OF THE X-VERT STUDY
Yavelov I.S.
MD, leading researcher, SRI of Physical-Chemical Medicine,
Federal Medical and Biological Agency of Russia, Moscow
Recently, much attention has been given to the use ofnew oral anticoagulants (NOAC) for the preventionof thrombotic events in patients at high risk. The effi-
cacy and safety of using NOAC registered in Russia is widely
discussed today. In September 2014, the results of the X-
VERT study investigating rivaroxaban were published. That
was the first prospective, multicenter, randomized, open
study into use of a NOAC in cardioversion in patients with
atrial fibrillation. According to the X-VERT study, rivaroxa-
ban appears to be an effective and safe alternative to vita-
min K antagonists and may alloow prompt cardioversion in
hemodynamically stable patients with paroxysmal non-
valvular atrial fibrillation.
KEYWORDS: cardioversion, non-valvular atrial fibrillation,
X-VERT, rivaroxaban, thrombosis prophylaxis
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EFFICACY AND SAFETY OF DABIGATRAN IN ELDERLY
PATIENTS WITH NON-VALVULAR ATRIAL 
FIBRILLATION IN CLINICAL PRACTICE 
(RESULTS OF THE MEDICARE STUDY)
Vorobyova N. M., Panchenko E. P.
Russian Cardiology Research and Production Complex,
Russia’s Ministry of Health, Moscow
T his review article tells about the results of theMedicare observational cohort study the purpose ofwhich was to obtain more information on efficacy and
safety of dabigatran in more than 130 thousand elderly
(over 65 years) patients with non-valvular atrial fibrillation
eligible for free medical care under the Medicare program
(USA). The obtained results are consistent with the results of
the previous studies — RE-LY and RELY-ABLE, and demon-
strate higher efficacy of dabigatran in reducing risk of
stroke, intracerebral hemorrhage and death compared to
warfarin. However, dabigatran is characterized by less safety
than warfarin, and associated with a higher risk of gastroin-
testinal bleeding.
KEYWORDS: atrial fibrillation, anticoagulant 
therapy, dabigatran
THROMBIN GENERATION TEST IN THE ESTIMATION 
OF EFFECTS OF ANTIPLATELET AGENTS IN PATIENTS 
WITH CORONARY HEART DISEASE AFTER PERCUTANEOUS
CORONARY INTERVENTION
Berezovskaya1,3 G.A., Smirnova2 O.A., 
Petrischev1,3 N.N., Papayan2 L.P., Karpenko3 M.A.,
Golovina2 O.G., Khromov-Borisov1 N.N.
1 St. Petersburg State Medical University named after aca-
demician I.P. Pavlov, St. Petersburg; 
2 Russian Research Institute of Hematology and Blood
Transfusion, FMBA of Russia, St. Petersburg; 
3 Federal North-West Medical Research Centre, the Ministry
of Health of the RF
A im: To explore the possibilities of using thrombingeneration test in platelet-rich and platelet-poorplasma to assess the impact of dual antiplatelet
therapy in patients with CHD after percutaneous coronary
intervention. Material and methods: The material for the
study was venous blood of 54 patients with CHD aged 53
to 77 years after percutaneous coronary intervention with
stent placing within a year and receiving clopidogrel and
aspirin in standard doses (75 and 75-100 mg daily, respec-
tively), and of 40 people comparable by age and sex,
without clinical manifestations of CHD and not receiving
the drugs for any other purpose. Thrombin generation
test was performed in platelet-rich and platelet-poor plas-
ma. Intravascular activation and induced platelet aggrega-
tion, as well as routine coagulation indicators, were evalu-
ated. Results: Administration of antiplatelet agents did not
affect the results of routine coagulation tests or intravas-
cular platelet activation. The evaluation of induced
platelet aggregation demonstrated that antiplatelet agents
had the most significant impact on collagen-induced
platelet aggregation (p = 10-7). The thrombogram showed
that in platelet-rich plasma the most significant impact of
antiaggregants was in a decrease in endogenous thrombin
potential (ETP; P = 0,0045) and peak thrombin concentra-
tion (PT; P = 4•10-6), and an increase in the time to peak
of the thrombin concentration (TTP; P = 0,0012).
Decreased velocity of thrombin generation (VI; P = 10-8)
was the most statistically relevant indicator.
Administration of antiplatelet agents had no effect on
thrombograms of thrombin generation tests performed in
platelet-poor plasma. Conclusion: Thrombin generation
tests in platelet-rich plasma can be used to evaluate the
effect of dual antiplatelet therapy. The most relevant indi-
cator is velocity of thrombin generation.
KEYWORDS: thrombin generation test, antiplatelet agents,
coronary heart disease, percutaneous coronary intervention
APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION
Shakhmatova O.O., Panchenko E. P.
Institute of Clinical Cardiology named after A.L.
Myasnikov, Russian Cardiology Research and Production
Complex, MH RF
C ardiovascular disease is the most common pathologyin Russia. Over 50% of deaths are caused by cardiovas-cular diseases, a significant proportion of which is
associated with systemic thromboembolism and stroke.
Atrial fibrillation significantly increases the incidence of
thrombotic events for the prophylaxis of which anticoagu-
lants are recommended. New oral anticoagulants (NOAC)
have been increasingly used recently, the administration of
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which does not require international normalized ratio con-
trol. The article tells about apixaban — the NOAC for the
treatment of patients with atrial fibrillation.
KEYWORDS: atrial fibrillation, new oral anticoagulants,
stroke, systemic thromboembolism, apixaban
PREVENTION OF RECURRENT ISCHEMIC EVENTS IN
PATIENTS AFTER MYOCARDIAL INFARCTION. NEW
OPTIONS FOR LONG-TERM DUAL ANTIPLATELET THERA-
PY. RESULTS OF THE PEGASUS-TIMI54 STUDY.
Averkov O.V.
Peoples’ Friendship University of Russia and City Hospital
#15 named after O.M.Filatov, Moscow
C ardiovascular diseases account for more than half ofall deaths in Russia. Among those, coronary heart dis-ease and myocardial infarction are the most chal-
lenging and associated with high mortality. Special atten-
tion is required to the management of patients throughout
a year after myocardial infarction. During that period, the
probability of recurrence of other ischemic events or car-
diac death is particularly high, the fact justifying the com-
bined use of two antiplatelet agents. The article tells about
the efficacy of long-term enhancement of the effect of
acetylsalicylic acid by ticagrelor in secondary prevention of
ischemic events in patients after MI (according the PEGA-
SUS-TIMI 54 study).
KEYWORDS: myocardial infarction, recurrent 
ischemic event, dual antiplatelet therapy, acetylsalicylic 
acid, ticagrelor
FAST SATURATION WITH WARFARIN IS A PREDICTOR 
OF EXCESSIVE HYPOCOAGULATION. ADJUSTING 
THE ALGORITHM FOR WARFARIN DOSAGE
Kropacheva1 E.S., Borovkov3 N.N., Vavilova4 T.V.,
Vereina5 N.K., Vorobyova6 N.A., Galkina2 I.S.,
Grekhova7 L.V., Grontkovskaya3 A. V., Donnikov2 A.E.,
Dobrovolskiy1 A.B., Zholobova5 N.I., Zagorodnikova4
K.A., Zateyschikov8 D.A. , Zemlyanskaya1 O.A., Zotova8
I.V., Kolevatova7 G.A., Kokh9 N.V., Lavrinov6 P.A.,
Lifshits9 G.I., Maksimova2 O.O., Mitroshkina1 M.O.,
Panchenko1 E.P., Rogozina6 A.S., Sinitsyn5 S.P.,
Slepukhina9 A., Sirotkina4 O.V., Titaeva1 E.V.,
Trofimov2 D.Y., Fedyushina3 O.G., Chulkov5 V.S.,
Tsvetovskaya9 G.A.
1 Institute of Clinical Cardiology named after A.L. Myas-
nikov, Russian Cardiology Research and Production
Complex, MH RF, Moscow.
2 ZAO «NPF DNA-Technology», Moscow.
3 Nizhny Novgorod State Medical Academy, Department of
Hospital Therapy.
4 Saint-Petersburg State Medical Academy named after 
I.I. Mechnikov, Department of Hospital Therapy. 
Course of Clinical Laboratory Diagnostics.
5 Chelyabinsk State Medical Academy, Department of
Internal Medicine and Endocrinology, City Department of
Hemostasis Pathology, CCH#11.
6 Northern Branch of Hematology Research Center,
Ministry of Health and Social Development of the RF,
Arkhangelsk.
7 Kirov Regional Cardiology Centre, Vyatka.
8 Academic Medical Center of the Department 
of Presidential Affairs of the RF, Moscow.
9 ICBFM SB RAS, laboratory of personalized medicine,
Novosibirsk.
T he article tells about results of a prospective follow-upof patients receiving warfarin and evaluates the keyfactors determining a safe maintenance dose. It was
found that achieving a first INR of ≥2,0 on day 3 and 5 after
start of warfarin therapy is evidently associated with exces-
sive anticoagulation (INR ≥4,0). Genotype evaluation
revealed dependence of warfarin saturation rate from car-
riage of CYP2C9 and VKORC1 allelic variants. Fast achieve-
ment of anticoagulant effect in the majority of cases is
shown to be related to the carriage of «unfavorable geno-
type» (CYP2C9 *2/*2 or *3/*3 or 2/*3 alleles or AA VKORC
allelic variant1, or concomitant carriage of two heterozygous
polymorphisms CYP2C9 and VKORC1). Based on the
obtained results, the authors concluded that INR blood test
on day 3–5 after initiation of therapy had high practical
value. The performed discriminant analysis determined the
clinical predictor of excessive anticoagulation due to over-
dose of warfarin — amiodarone therapy. The findings served
as the basis for the modification of the current algorithm
for warfarin dosing adjustment.
KEYWORDS: warfarin, dosing adjustment algorithm,
predictors of excessive anticoagulation
LIST OF ABSTRACTS OF THIS ISSUE
LIST OF ABSTRACTS OF THIS ISSUE
115С П Е Ц И А Л И З И Р О В А Н Н Ы Й  М Е Д И Ц И Н С К И Й  Ж У Р Н А Л 1–2015 АТЕРОТРОМБОЗ
OPTIONS FOR MEDICATION TREATMENT OF CHRONIC
THROMBOEMBOLIC PULMONARY HYPERTENSION
Martynyuk T.V., Dadacheva Z.K., Chazova I.E.
Hypertension Unit, Myasnikov Research Institute of
Clinical Cardiology, Russian Cardiology Research and
Production Complex, MH RF
C hronic thromboembolic pulmonary hypertension(CTEPH) is a unique, potentially curable form of pul-monary hypertension (PH) characterized by oblitera-
tion of elastic pulmonary arteries by organized thrombus.
Increase in pulmonary vascular resistance (PVR) and pul-
monary artery pressure is also associated with a progressive
remodelling of the distal pulmonary vascular bed. Standard
treatment for CTEPH is pulmonary thrombendarterectomy.
Adequate medication therapy means lifelong intake of anti-
coagulants. Warfarin is the drug of first choice. Medical ther-
apies used in the treatment of pulmonary arterial hyperten-
sion (PAH) are often considered for use in inoperable
patients, or for patients who have residual PH. Prostanoids,
phosphodiesterase type 5 inhibitors and endothelin recep-
tor antagonists have been studied in a number of open
studies of patients with inoperable CTEPH. In the BENEFIT
study, on week 16 of treatment bosentan contributed to a
significant reduction in PVR and an increase in cardiac out-
put; however, compared with placebo, it did not improve
exercise tolerance after 6-min walk test. CHEST-1 (a ran-
domized, placebo-controlled study) demonstrated the effi-
cacy and safety of riociguat — a representative of a new
class of stimulators of soluble guanylate cyclase. In
September 2014, the drug was approved for the treatment
of patients with inoperable and residual CTEPH in this
country.
KEYWORDS: pulmonary hypertension, chronic throm-
boembolic pulmonary hypertension, thrombendarterecto-
my, bosentan, prostanoids, sildenafil, riociguat.
LONG-TERM ANTITHROMBOTIC THERAPY 
AT HIGH RISK OF THROMBOSIS AND BLEEDING. 
CLINICAL OBSERVATION
E.P. Panchenko, A.L. Komarov, 
M.A. Saidova, E.V. Merkulov, E.S. Kropachyova, 
O.O. Shakhmatova, R.V. Kaziev
Institute of Clinical Cardiology named after A.L.
Myasnikov, Russian Cardiology Research and Production
Complex, Ministry of Health of the RF
P atients after heart surgery require antithrombotictherapy. Long-term anticoagulation therapy is espe-cially relevant for patients who were implanted with
a cardiac device. Unfortunately, antithrombotic therapy is
associated with increased incidence of hemorrhage requir-
ing long-term follow-up of patients and adequate selection
of antithrombotic therapy. The article reviews a clinical case
of long-term antithrombotic therapy at high risk of throm-
bosis and bleeding following implantation of the Watchman
Device.
KEYWORDS: atrial fibrillation, antithrombotic therapy,
anticoagulants, implantable device, Watchman closer device
WARFARIN PHARMACOGENETICS
Kropacheva E.S.PhD in Med.
Associate researcher, Laboratory of Clinical
Atherothrombotic Problems, Department of Angiology,
Myasnikov Research Institute of Clinical Cardiology,
RCRPC, MH RF, Moscow
